// <auto-generated/>
// Contents of: hl7.fhir.r4.core version: 4.0.1
// Minimum TypeScript Version: 3.7
// FHIR ValueSet: http://hl7.org/fhir/ValueSet/research-study-phase|4.0.1
import { Coding } from '../fhir.js';
/**
 * Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.
 */
export const ResearchStudyPhaseValueSet = {
    /**
     * early-phase-1: Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0.
     */
    EarlyPhase1: new Coding({
        display: "Early Phase 1",
        code: "early-phase-1",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    }),
    /**
     * n-a: Trials without phases (for example, studies of devices or behavioral interventions).
     */
    NA: new Coding({
        display: "N/A",
        code: "n-a",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    }),
    /**
     * phase-1: Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
     */
    Phase1: new Coding({
        display: "Phase 1",
        code: "phase-1",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    }),
    /**
     * phase-1-phase-2: Trials that are a combination of phases 1 and 2.
     */
    Phase1Phase2: new Coding({
        display: "Phase 1/Phase 2",
        code: "phase-1-phase-2",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    }),
    /**
     * phase-2: Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
     */
    Phase2: new Coding({
        display: "Phase 2",
        code: "phase-2",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    }),
    /**
     * phase-2-phase-3: Trials that are a combination of phases 2 and 3.
     */
    Phase2Phase3: new Coding({
        display: "Phase 2/Phase 3",
        code: "phase-2-phase-3",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    }),
    /**
     * phase-3: Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
     */
    Phase3: new Coding({
        display: "Phase 3",
        code: "phase-3",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    }),
    /**
     * phase-4: Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
     */
    Phase4: new Coding({
        display: "Phase 4",
        code: "phase-4",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    }),
};
/**
 * Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.
 */
export var ResearchStudyPhaseValueSetEnum;
(function (ResearchStudyPhaseValueSetEnum) {
    /**
     * early-phase-1: Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0.
     */
    ResearchStudyPhaseValueSetEnum["EarlyPhase1"] = "early-phase-1";
    /**
     * n-a: Trials without phases (for example, studies of devices or behavioral interventions).
     */
    ResearchStudyPhaseValueSetEnum["NA"] = "n-a";
    /**
     * phase-1: Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
     */
    ResearchStudyPhaseValueSetEnum["Phase1"] = "phase-1";
    /**
     * phase-1-phase-2: Trials that are a combination of phases 1 and 2.
     */
    ResearchStudyPhaseValueSetEnum["Phase1Phase2"] = "phase-1-phase-2";
    /**
     * phase-2: Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
     */
    ResearchStudyPhaseValueSetEnum["Phase2"] = "phase-2";
    /**
     * phase-2-phase-3: Trials that are a combination of phases 2 and 3.
     */
    ResearchStudyPhaseValueSetEnum["Phase2Phase3"] = "phase-2-phase-3";
    /**
     * phase-3: Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
     */
    ResearchStudyPhaseValueSetEnum["Phase3"] = "phase-3";
    /**
     * phase-4: Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
     */
    ResearchStudyPhaseValueSetEnum["Phase4"] = "phase-4";
})(ResearchStudyPhaseValueSetEnum || (ResearchStudyPhaseValueSetEnum = {}));
//# sourceMappingURL=ResearchStudyPhaseValueSet.js.map